Betalin Therapeutics
Dr. Moti Friedman has work experience as the Chief Executive Officer at Betalin Therapeutics Ltd. since June 2023. Prior to that, they were the Managing Partner at BrightNet - the Institute of Business Research starting from 1994.
Dr. Moti Friedman has a B.Sc. in Industrial Engineering from Tel Aviv University. Dr. Moti also holds an MSM degree in Management, which they earned from Boston University and Ben-Gurion University of the Negev. Additionally, Dr. Friedman obtained a Ph.D. in Communication Technology from the University of Leicester in England.
Betalin Therapeutics
Betalin Therapeutics develops a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP).